- Home
- SLGB vs MNOV Comparison
SLGB vs MNOV Comparison
Compare SLGB & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | MNOV |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 72.7M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SLGB | MNOV |
|---|---|---|
| Price | $1.20 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 297.4K | 93.4K |
| Earning Date | 02-16-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $99,438,843.00 | $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.69 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $0.92 | $1.13 |
| 52 Week High | $6.08 | $2.06 |
Technical Indicators
Market Signals| Indicator | SLGB | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 70.91 |
| Support Level | N/A | $1.43 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 92.55 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.